Thrombotech Receives Regulatory Approval for Stroke Medicine Trials in the US

Wednesday, Mar 28 2012

Thrombotech Ltd., a biotechnology company based on cutting-edge stroke research at the Hadassah University Medical Center, has received approval from the United States' Food and Drug Administration (FDA) to expand clinical trials to the US for its lead product, THR-18. This medicine is designed to improve the safety and efficacy of tPA, the currently available treatment for ischemic stroke.

THR-18 is designed to allow tPA to dissolve blood clots easily, extending its short therapeutic time window and diminishing life-threatening side effects. It is currently undergoing Phase IIA clinical trials at several hospitals in Israel, including Hadassah, and is awaiting regulatory approvals in Europe and India.

"This important regulatory approval serves as external validation for our development program and the quality of the science and management behind the company," says Thrombotech Chief Executive Officer Dr. Ruth Ben Yakar. "It will enable us to recruit more patients in some of the leading medical centers specializing in stroke in the US and move towards commercialization of the therapy for this serious medical condition."

Hadasit, Hadassah's technology transfer company, holds a 24% stake in Thrombotech. Commenting on the approval, Ophir Shahaf, Chief Executive Officer of Hadasit Bio-Holdings, Hadasit's publicly traded subsidiary, stated: "We are proud to expand the clinical trial to medical centers in the US, a world leader in Central Nervous System therapeutics and stroke treatment in particular."


No comments yet.
First Name
Enter this word:

Related Stories

alt_text WHO Head Praises Hadassah Hospital

Director of the World Health Organization praises Hadassah's pediatric hemato-oncology ward.


Wednesday, Mar 14 2018

A Record Year for Transplants at Hadassah

The Hadassah Medical Organization completed the past year with a record number of transplants in its Transplantation Unit, one of the largest and most active in Israel.


Thursday, Mar 8 2018

Hadassah Physicians Travel to Mexico to Repair Cleft Palates

This week, a team of Hadassah physicians are performing surgery on children with cleft palates in Mexico. This is a part of the continuing impact that Hadassah is having on health in Mexico.


Thursday, Mar 8 2018

Hadassah Performs Rare Operation on Baby About to be Born

A baby suffering from a complex congenital disorder called Stickler Syndrome was delivered successfully following the performance by a Hadassah Medical Organization multidisciplinary team of a rare operation to unblock its air passages.


Donation Questions


(800) 928-0685

Membership Questions


(800) 664-5646

Missions Department


(800) 237-1517

Contact Us

40 Wall Street

New York, NY 10005


More ›

Show More